Normax In The News

Normax In The NewsPeter A. Jensen2023-05-05T11:08:52+00:00

Cork biotech firm secures $300 million funding for budget mRNA vaccine facilities

Charlie Taylor

16 July 2022

Cork firm Normax secures €300m to make cheaper mRNA vaccines

Leigh McGowran

18 July 2022

With €300m in hand, Normax looks to slash mRNA costs

Dan Stanton

21 July 2022

Manufacturing roundup: mRNA manufacturer nets $300M+ investment to scale research

Tyler Patchen

21 July 2022

The biggest European biotech investments in July 2022

Jonatan Smith

3 August 2022

How mRNA vaccines are democratising the development of healthcare

Lara Williams

12 August 2022

Normax Biomed opts for Dublin for first vaccine factory

Charlie Taylor

19 November 2022

Normax Biomed to create ‘hundreds of jobs’ at planned Dublin site

Blathnaid O’Dea

23 November 2022

Ensuring capital for the next generation

Business Post

24 November 2022

Bright future for careers in pharma and life sciences

John Daly

15 December 2022

Bright future for careers in pharma and life sciences

John Daly

15 December 2022

Normax and MTIF take mRNA tech to UK Uni

Millie Nelson

23 January 2023

New BioXP system in partnership with Normax

Editorial Board

02 February 2023

Revolutionary new social platform offers a lifeline for Parkinson’s patients

Lily Ramsey

18 April 2023

Editorials and Thought Leadership

EDITORIAL
The time for mRNA vaccine equality across the globe

Peter A Jensen
CEO & Chairman, Normax Biomed
8 September 2022

Peter Jensen, CEO and Chairman, Normax delves into why it’s time for mRNA vaccine equality to be established across the globe. He also goes on to explain how mRNA vaccines can help drive down the costs of vaccines, save more lives and support the long-term sustainable battle against future pandemics world-wide. - European Pharmaceutical Manufacturer.

Read Editorial

FOUNDER/CEO SPOTLIGHT SERIES
Securing $300 million in funding ahead of a planned IPO

Peter A Jensen
CEO & Chairman, Normax Biomed
16 NOV 2022

The Raising Capital Summit 2022 will bring together founders and investors to discuss the outlook for investment in Irish companies in a climate of global economic uncertainty and a geo-political crisis in Eastern Europe. It provides a unique opportunity for founders and executives to hear from the investment community on how the environment is shifting and how this impacts their chances of gaining access to capital. - Raising Capital Summit 2022

Read Agenda

Normax interviewed on ‘The Road to Ireland’ by Nigel Walker, CEO, That’s Nice

Peter A Jensen
CEO & Chairman, Normax Biomed
6 September 2022

At the National Institute of Bioprocessing Research and Training (NIBRT) at University College Dublin (UCD), Normax was interviewed by Nigel Walker, CEO of That’s Nice, a Science Agency, for The Road To Ireland campaign by Pharma Almanac, in cooperation with the PDA Ireland Chapter. As Pharma’s Almanac embarks on the 4th installment of our epic Road To series, Normax takes part in the ride, to share the latest developments of Normax, based in Cork, Ireland

Learn More

Media Contact

Berkeley Communications
+44 118 909 0909
normax@berkeleypr.com

Visit Website

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.